Calcific uremic arteriolopathy (calciphylaxis): Successful treatment with sodium thiosulfate in spite of elevated serum phosphate

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue SUPPL. 1, 2009, Pages

  Kalisiak, Michal ^a   Courtney, Mark ^a   Lin, Andrew ^a   Brassard, Alain ^a,b  

^a University Dermatology Center   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CARBONATE; COLCHICINE; DOXAZOSIN; HYDROMORPHONE; LABETALOL; NIFEDIPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; SODIUM THIOSULFATE; ANTIOXIDANT; THIOSULFATE;

ADULT; ANAMNESIS; BONE SCINTISCANNING; CALCINOSIS; CALCIUM BLOOD LEVEL; CASE REPORT; CONFERENCE PAPER; DEBRIDEMENT; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY TUBULE NECROSIS; LEG PAIN; LEG ULCER; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SOFT TISSUE CALCIFICATION; WOUND HEALING; BLOOD; COMORBIDITY; DRUG EFFECT; MIDDLE AGED; PROGNOSIS; REVIEW; RISK FACTOR;

ANTIOXIDANTS; CALCIPHYLAXIS; COMORBIDITY; FEMALE; HUMANS; HYDROMORPHONE; MIDDLE AGED; PHOSPHATES; PROGNOSIS; RISK FACTORS; THIOSULFATES; WOUND HEALING;

EID: 68349123830     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.00007     Document Type: Conference Paper

References (74)

1. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008; 17:629-34.
2. Dauden E, Onate MJ. Calciphylaxis. Dermatol Clin 2008;26:557-68, ix.
3. Arseculeratne G, Evans AT, Morley SM. Calciphylaxis-a topical overview. J Eur Acad Dermatol Venereol 2006;20:493-502.
4. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997;122:1083-9.
5. Wong JJ, Laumann A, Martinez M. Calciphylaxis and antiphospholipid antibody syndrome. J Am Acad Dermatol 2000;42:849.
6. Riegert-Johnson DL, Kaur JS, Pfeifer EA. Calciphylaxis associated with cholangiocarcinoma treated with low-molecular-weight heparin and vitamin K. Mayo Clin Proc 2001;76:749-52.
7. Raper RF, Ibels LS. Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis. Nephron 1985;39:389-92.
8. Ozbalkan Z, Calguneri M, Onat AM, Ozturk MA. Development of calciphylaxis after long-term steroid and methotrexate use in a patient with rheumatoid arthritis. Intern Med 2005;44:1178-81.
9. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008;3:1139-43.
10. Mastruserio DN, Nguyen EQ, Nielsen T, et al. Calciphylaxis associated with metastatic breast carcinoma. J Am Acad Dermatol 1999;41:295-8.
11. Kutlu NO, Aydin NE, Aslan M, et al. Malignant melanoma of the soft parts showing calciphylaxis. Pediatr Hematol Oncol 2003;20:141-6.
12. Korkmaz C, Dundar E, Zubaroglu I. Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency. Clin Rheumatol 2002;21:66-9.
13. Goff HW, Grimwood RE. A case of calciphylaxis and chronic myelomonocytic leukemia. Cutis 2005;75:325-8.
14. De R I, Filotico R, Cea M, et al. Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report. Ann Ital Med Int 2004;19:283-7.
15. Cockerell CJ, Dolan ET. Widespread cutaneous and systemic calcification (calciphylaxis) in patients with the acquired immunodeficiency syndrome and renal disease. J Am Acad Dermatol 1992;26:559-62.
16. Bosler DS, Amin MB, Gulli F, Malhotra RK. Unusual case of calciphylaxis associated with metastatic breast carcinoma. Am J Dermatopathol 2007;29:400-3.
17. Bamberger N, Emmerich J, Fiessinger JN. Calciphylaxis in patients with human immunodeficiency virus infection and renal disease. J Am Acad Dermatol 1993;28:135-6.
18. Munavalli G, Reisenauer A, Moses M, et al. Weight loss-induced calciphylaxis: potential role of matrix metalloproteinases. J Dermatol 2003;30:915-9.
19. Barri YM, Graves GS, Knochel JP. Calciphylaxis in a patient with Crohn's disease in the absence of end-stage renal disease. Am J Kidney Dis 1997;29:773-6.
20. Goyal S, Huhn KM, Provost TT. Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: possible aetiological role of chemotherapy. Br J Dermatol 2000;143:1087-90.
21. Ferreres JR, Marcoval J, Bordas X, et al. Calciphylaxis associated with alcoholic cirrhosis. J Eur Acad Dermatol Venereol 2006;20:599-601.
22. Goli AK, Goli SA, Shah LS, et al. Calciphylaxis: a rare association with alcoholic cirrhosis. Are deficiencies in protein C and S the cause? South Med J 2005;98:736-9.
23. Lim SP, Batta K, Tan BB. Calciphylaxis in a patient with alcoholic liver disease in the absence of renal failure. Clin Exp Dermatol 2003;28:34-6.
24. Ahmed S, O'Neill KD, Hood AF, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001;37:1267-76.
25. Bleyer AJ, Choi M, Igwemezie B, et al. A case control study of proximal calciphylaxis. Am J Kidney Dis 1998;32:376-83.
26. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001;60:324-32.
27. Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007;56:569-79.
28. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002;61:2210-7.
29. Kriskovich MD, Holman JM, Haller JR. Calciphylaxis: is there a role for parathyroidectomy? Laryngoscope 2000;110:603-7.
30. Galimberti RL, Farias ER, Parra IH, et al. Cutaneous necrosis by calcific uremic arteriolopathy. Int J Dermatol 2005;44:101-6.
31. Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 2008;58:458-71.
32. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15:172-86.
33. Bleibel W, Hazar B, Herman R. A case report comparing various radiological tests in the diagnosis of calcific uremic arteriolopathy. Am J Kidney Dis 2006;48:659-61.
34. Lazorik FC, Friedman AK, Leyden JJ. Xeroradiographic observations in four patients with chronic renal disease and cutaneous gangrene. Arch Dermatol 1981;117:325-8.
35. Norris B, Vaysman V, Line BR. Bone scintigraphy of calciphylaxis: a syndrome of vascular calcification and skin necrosis. Clin Nucl Med 2005;30:725-7.
36. Hayden MR, Goldsmith D, Sowers JR, Khanna R. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol 2008;40:443-51.
37. Martin R. Mysterious calciphylaxis: wounds with eschar - to debride or not to debride? Ostomy Wound Manage 2004;50: 64-70.
38. Hafner J, Keusch G, Wahl C, et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995;33:954-62.
39. Hafner J, Keusch G, Wahl C, Burg G. Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. Vasa 1998;27:137-43.
40. Milas M, Weber CJ. Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism. Surgery 2004;136:1252-60.
41. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996;7:978-82.
42. Girotto JA, Harmon JW, Ratner LE, et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 2001;130:645-50.
43. Younis N, Sells RA, Desmond A, et al. Painful cutaneous lesions, renal failure and urgent parathyroidectomy. J Nephrol 2002; 15:324-9.
44. Duffy A, Schurr M, Warner T, Chen H. Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol 2006;13:96-102.
45. Couto FM, Chen H, Blank RD, Drezner MK. Calciphylaxis in the absence of end-stage renal disease. Endocr Pract 2006; 12:406-10.
46. Arch-Ferrer JE, Beenken SW, Rue LW, et al. Therapy for calciphylaxis: an outcome analysis. Surgery 2003;134:941-4.
47. Basile C, Montanaro A, Masi M, et al. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 2002;15:676-80.
48. Basile C. Hyperbaric oxygen therapy in the treatment of calciphylaxis? Yes, more than hope. Kidney Int 2002;62:2300.
49. Podymow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant 2001;16:2176-80.
50. Raymond CB, Wazny LD. Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm 2008;65:1419-29.
51. Monney P, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004;19:2130-2.
52. Shiraishi N, Kitamura K, Miyoshi T, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006;48:151-4.
53. Musso CG, Enz PA, Guelman R, et al. Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate. Perit Dial Int 2006;26:717-8.
54. Hanafusa T, Yamaguchi Y, Tani M, et al. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 2007;57:1021-5.
55. da Costa JB, da Costa AG, Gomes MM. Pamidronate as a treatment option in calciphylaxis. J Eur Acad Dermatol Venereol 2008;22:1128-30.
56. Robinson MR, Augustine JJ, Korman NJ. Cinacalcet for the treatment of calciphylaxis. Arch Dermatol 2007;143:152-4.
57. Sharma A, Burkitt-Wright E, Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol 2006;155:1295-7.
58. Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet - an alternative to parathyroidectomy? Nephrol Dial Transplant 2006;21: 1999-2004.
59. Mohammed IA, Sekar V, Bubtana AJ, et al. Proximal calciphylaxis treated with calcimimetic 'cinacalcet.' Nephrol Dial Transplant 2008;23:387-9.
60. Pallure V, Comte C, Leray-Mouragues H, Dereure O. Cinacalcet as first-line treatment for calciphylaxis. Acta Derm Venereol 2008;88:62-3.
61. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004;43:1104-8.
62. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 2005;20:1260-2.
63. Brucculeri M, Cheigh J, Bauer G, Serur D. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005;18:431-4.
64. Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 2006;1:1161-6.
65. Hayden MR, Tyagi SC, Kolb L, et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005;4:4.
66. Meissner M, Bauer R, Beier C, et al. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology 2006;212:373-6.
67. Tokashiki K, Ishida A, Kouchi M, et al. Successful management of critical limb ischemia with intravenous sodium thiosulfate in a chronic hemodialysis patient. Clin Nephrol 2006;66:140-3.
68. Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol 2007;143: 269-70.
69. Ackermann F, Levy A, Daugas E, et al. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol 2007; 143:1336-7.
70. Subramaniam K, Wallace H, Sinniah R, Saker B. Complete resolution of recurrent calciphylaxis with long-term intravenous sodium thiosulfate. Australas J Dermatol 2008;49:30-4.
71. Mataic D, Bastani B. Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail 2006;28:361-3.
72. Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009;53:133-7.
73. Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007;2:258-63.
74. Linfert DR, Schell JO, Fine DM. Treatment of nephrogenic systemic fibrosis: limited options but hope for the future. Semin Dial 2008;21:155-9.